These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 20550118

  • 1. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
    Hu Q, Yin L, Jagusch C, Hille UE, Hartmann RW.
    J Med Chem; 2010 Jul 08; 53(13):5049-53. PubMed ID: 20550118
    [Abstract] [Full Text] [Related]

  • 2. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
    Hu Q, Jagusch C, Hille UE, Haupenthal J, Hartmann RW.
    J Med Chem; 2010 Aug 12; 53(15):5749-58. PubMed ID: 20684610
    [Abstract] [Full Text] [Related]

  • 3. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
    Hu Q, Negri M, Jahn-Hoffmann K, Zhuang Y, Olgen S, Bartels M, Müller-Vieira U, Lauterbach T, Hartmann RW.
    Bioorg Med Chem; 2008 Aug 15; 16(16):7715-27. PubMed ID: 18674917
    [Abstract] [Full Text] [Related]

  • 4. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
    Hille UE, Hu Q, Vock C, Negri M, Bartels M, Müller-Vieira U, Lauterbach T, Hartmann RW.
    Eur J Med Chem; 2009 Jul 15; 44(7):2765-75. PubMed ID: 19211174
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
    Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW.
    J Med Chem; 2008 Aug 28; 51(16):5009-18. PubMed ID: 18672868
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
    Wang M, Fang Y, Gu S, Chen F, Zhu Z, Sun X, Zhu J.
    Eur J Med Chem; 2017 May 26; 132():157-172. PubMed ID: 28350999
    [Abstract] [Full Text] [Related]

  • 7. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW, Eisner JR, Moore WR, Schotzinger RJ, Hoekstra WJ.
    Bioorg Med Chem Lett; 2014 Jun 01; 24(11):2444-7. PubMed ID: 24775307
    [Abstract] [Full Text] [Related]

  • 8. CYP17 inhibitors for prostate cancer treatment--an update.
    Moreira VM, Salvador JA, Vasaitis TS, Njar VC.
    Curr Med Chem; 2008 Jun 01; 15(9):868-99. PubMed ID: 18473796
    [Abstract] [Full Text] [Related]

  • 9. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
    Pinto-Bazurco Mendieta MA, Negri M, Hu Q, Hille UE, Jagusch C, Jahn-Hoffmann K, Müller-Vieira U, Schmidt D, Lauterbach T, Hartmann RW.
    Arch Pharm (Weinheim); 2008 Oct 01; 341(10):597-609. PubMed ID: 18720339
    [Abstract] [Full Text] [Related]

  • 10. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.
    Hu Q, Negri M, Olgen S, Hartmann RW.
    ChemMedChem; 2010 Jun 07; 5(6):899-910. PubMed ID: 20437447
    [Abstract] [Full Text] [Related]

  • 11. New benzothieno[2,3-c]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and in silico ADME profile studies.
    Khalil NA, Ahmed EM, Zaher AF, Sobh EA, El-Sebaey SA, El-Zoghbi MS.
    J Enzyme Inhib Med Chem; 2021 Dec 07; 36(1):1839-1859. PubMed ID: 34338119
    [Abstract] [Full Text] [Related]

  • 12. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S, Hartmann RW.
    Pharmazie; 2017 Sep 01; 72(9):529-536. PubMed ID: 29441980
    [Abstract] [Full Text] [Related]

  • 13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
    Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046
    [Abstract] [Full Text] [Related]

  • 14. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
    Wachall BG, Hector M, Zhuang Y, Hartmann RW.
    Bioorg Med Chem; 1999 Sep 01; 7(9):1913-24. PubMed ID: 10530940
    [Abstract] [Full Text] [Related]

  • 15. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q, He C, Lao K, Luo G, You Q, Xiang H.
    Steroids; 2019 Oct 01; 150():108384. PubMed ID: 30885648
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM.
    J Med Chem; 2005 Apr 21; 48(8):2972-84. PubMed ID: 15828836
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F.
    Curr Med Chem; 2005 Apr 21; 12(14):1623-9. PubMed ID: 16022662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.